应用2-[18F]-氟-2-脱氧-D-葡萄糖正电子发射断层显像预测胰腺导管腺癌术前化疗的病理缓解
研究纳入28例仅接受新辅助化疗后手术的胰腺导管腺癌患者,术前均行F-18 FDG-PET检查,按切除标本病理坏死程度分为非缓解组(≤50%坏死)与缓解组(>50%坏死)。缓解组平均SUVmax高于非缓解组(9.00±1.78 vs 4.26±2.35,p<0.001),以SUVmax 9.28为界值预测缓解的敏感度80%、特异度95.7%、准确率92.9%。作者认为SUVmax可能作为预测新辅助化疗病理缓解的生物标志物。
要点
- 缓解组平均SUVmax 9.00±1.78,高于非缓解组4.26±2.35(p<0.001)。
- 以SUVmax 9.28为界值预测病理缓解,敏感度80%、特异度95.7%、准确率92.9%。
- 病理分组依据切除标本坏死比例:≤50%为非缓解,>50%为缓解。
核心结论
- F-18 FDG-PET的SUVmax可能作为预测胰腺导管腺癌患者新辅助化疗病理缓解的生物标志物。
研究设计与样本
- 研究纳入28例仅接受新辅助化疗后手术的胰腺导管腺癌患者,所有患者在新辅助化疗前接受F-18 FDG-PET检查,切除标本按胰腺癌分类(第7版)进行病理评估。
诊断标准与关键数值
- 病理分组:非缓解组(1a和1b级)标本坏死≤50%,缓解组(2-3级)标本坏死>50%;区分两组的SUVmax最佳界值为9.28,预测缓解组的敏感度80%、特异度95.7%、准确率92.9%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To determine whether the pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma (PDAC) can be predicted using 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography (F-18 FDG-PET).
MATERIALS AND METHODS: Twenty-eight patients with PDAC who underwent only neoadjuvant chemotherapy (NAC) before surgery were enrolled in the study. All patients had F-18 FDG-PET examinations before NAC. The resected specimen was pathologically evaluated according to the Classification of Pancreatic Carcinoma (7th edn). Patients were categorised into a non-response group and a response group based on the pathological findings. The non-response group (Grades 1a and 1b) showed ≤50% necrosis in the specimen, while the specimens of the response group (Grades 2-3) showed >50% necrosis. The maximum standardised uptake values (SUVmax) of the tumours on F-18 FDG-PET were measured. The mean values of SUVmax were compared between the two groups. The diagnostic performance of SUVmax in distinguishing the two groups was also evaluated using receiver operating characteristic analysis.
RESULTS: The mean SUVmax of the response group was higher than that of the non-response group (9.00 ± 1.78 versus 4.26 ± 2.35; p<0.001). The optimal cut-off value of SUVmax was 9.28 for distinguishing the two groups. The sensitivity, specificity, and accuracy for the prediction in the response group were 80%, 95.7%, and 92.9%, respectively.
CONCLUSIONS: SUVmax on F-18 FDG-PET may be useful as a biomarker to predict the pathological response to NAC in patients with PDAC.
引用
- Tabata, Nishie, Shimomura, et al. Prediction of pathological response to preoperative chemotherapy for pancreatic ductal adenocarcinoma using 2-[18F]-fluoro-2-deoxy-d-glucose positron-emission tomography. Clin Radiol. 2022. PMID: 35410786. doi:10.1016/j.crad.2022.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。